Canadian Active & Maintenance Modified Pentasa Study

PHASE3CompletedINTERVENTIONAL
Enrollment

288

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Active Ulcerative ColitisRemission of Ulcerative Colitis
Interventions
DRUG

5-ASA (5-Aminosalicylate)

500 mg tablet (modified extended release)

DRUG

5-ASA (5-Aminosalicylate)

500 mg tablet

Trial Locations (27)

Unknown

University of Calgary, Faculty of Medicine, Calgary

Castledowns Medicentre, Edmonton

Investigational site, Brandon

Hilyard Place Building A, Saint John

Barrie GI Associates, Barrie

Investigational site, Greater Sudbury

Investigational site, Guelph

St. Joseph's Healthcare, Hamilton

Investigational site, Oshawa

Investigational site - Phenix Building, Ottawa

Ottawa General Hospital, Ottawa

Digestive Health Clinic, Richmond Hill

Investigational site, Sarnia

Investigational site, Thunder Bay

JJ Dig Research Ltd, Toronto

Keele Medical Place, Toronto

St. Michael's Hospital, Toronto

Toronto Digestive Disease Association (TDDA), Toronto

Hotel Dieu Grace Hospital, Windsor

Investigational site, Windsor

Investigational site, Woodstock

Hotel Dieu de Levis, Lévis

Alpha Recherche Clinique Inc., Loretteville

Hopital Maissonneuve Rosemont, Montreal

MUHC-Royal Victoria Hospital, Montreal

Gastro Centre Hospitalier Universitaire de Québec/St-François-d'Assise Hospital, Québec

L'Hotel Dieu de Quebec, Québec

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY

NCT00603733 - Canadian Active & Maintenance Modified Pentasa Study | Biotech Hunter | Biotech Hunter